BioVie (NASDAQ:BIVI) Issues Quarterly Earnings Results

BioVie (NASDAQ:BIVI) issued its quarterly earnings results on Tuesday. The company reported ($0.46) EPS for the quarter, Zacks reports.

BioVie Stock Down 3.2 %

Shares of BIVI stock traded down $0.06 on Tuesday, reaching $1.80. The stock had a trading volume of 400,384 shares, compared to its average volume of 949,359. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10. The firm has a market capitalization of $31.99 million, a price-to-earnings ratio of -0.16 and a beta of 0.47. The firm’s 50-day moving average is $2.20 and its two-hundred day moving average is $2.29.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.